Find Academic Supervisors

Jennifer S CarewView profile

Professor

• Translational Oncology
• Hematological Malignancies
• Drug Resistance Mechanisms
• +4 more

Jennifer S Carew, PhD, is a Professor in the Department of Medicine at the University of Arizona and Co-Director of the Hematological Malignancies Disease Team at the University of Arizona Cancer Center. Her translational research bridges mechanistic studies on experimental anticancer agents with early-phase clinical trials, focusing on overcoming drug resistance in hematological malignancies. PhD, University of Texas MD Anderson Cancer Center (mitochondrial defects in chronic lymphocytic leukemia) Postdoctoral Research, St. Jude Children’s Research Hospital (drug resistance in hematological malignancies) Dr. Carew's research emphasizes targeting regulators of protein turnover (e.g., ubiquitin-proteasome, autophagy) and epigenetic stability in cancers like multiple myeloma and leukemia. Her work includes developing lysosomal autophagy inhibitors (e.g., ROC-325), exploring oncolytic viruses, and combining novel agents with standard therapies to enhance efficacy. Her lab utilizes proteomic and pharmacodynamic analyses to validate drug mechanisms, such as NEDD8 inhibition (MLN4924) in leukemia, and investigates tumor suppressor roles of autophagy genes in myeloid neoplasms. Clinical translation includes investigator-initiated trials for hematological malignancies and advanced solid tumors. Dr. Carew holds multiple patents and has received institutional recognition from the American Cancer Society, Leukemia and Lymphoma Society, and Voelcker Foundation. She collaborates extensively with clinical teams to advance preclinical findings into therapeutic strategies, particularly for renal cell carcinoma, soft tissue sarcomas, and leukemias.

Mark A. NelsonView profile

Professor

• Cancer Biology
• Epigenetics
• Molecular Diagnostics
• +3 more

Mark A. Nelson is a Professor in the Department of Pathology at the University of Arizona. His research focuses on inflammation and tumor progression/metastasis, racial disparities in cancer, and molecular diagnosis of cancer and genetic diseases. Key research themes include: Epigenetic markers for cancer detection (e.g., Sentinel-MPE liquid biopsy test) Immune interactions in tumor microenvironments Health equity and diagnostic innovation Current projects involve: Cell-free DNA methylation analysis for pleural effusion diagnostics Interdisciplinary studies on tumor-infiltrating lymphocytes Nanoparticle-based immunotherapy development He leads the Nelson Lab and has contributed to high-impact publications in Science , Nature Communications , and Mayo Clinic Proceedings .

• Pulmonary Medicine
• Critical Care
• Allergy and Immunology
• +10 more

Neil Trivedi, MD , is a Professor in the School of Medicine at the University of California, San Francisco (UCSF) . His clinical and research expertise lies at the intersection of pulmonary medicine, critical care, and immunology, with a focus on mast cell biology and lung transplantation immunology. Dr. Trivedi completed his MD at UCLA and underwent residency and fellowship training in Internal Medicine and Pulmonary/Critical Care at UCSF. He has also completed training in diversity, equity, and inclusion, reflecting a commitment to equitable healthcare and research practices. His research interests include tryptase biology , lung allograft rejection , biomarker discovery , and genomic and proteomic analysis of mast cell disorders . He has led NIH- and VA-funded research projects investigating the role of mast cell proteases in disease and developing diagnostic tools for early detection of transplant rejection. Dr. Trivedi's publication history reveals a strong trend in translational immunology and pulmonary disease. His recent work focuses on genetically defined reference ranges for tryptase, the development of anti-tryptase therapies for severe asthma, and biomarker validation for lung nodule characterization and transplant rejection. These studies highlight a consistent effort to bridge molecular discovery with clinical diagnostics and therapeutics. He has not been awarded any scientific prizes listed in the provided text, though his work has been cited extensively and featured in high-impact journals such as Cell , Blood Advances , and Nature Genetics . Dr. Trivedi collaborates extensively with leading researchers, particularly Dr. George Caughey, and contributes to both basic science and clinical studies. His work on lung allograft rejection and mast cell disorders has implications for improving outcomes in transplant recipients and patients with severe allergic and inflammatory conditions. He is affiliated with research networks in tryptase, mast cells, and transplantation and has contributed to both primary research and review chapters in authoritative texts such as the Handbook of Proteolytic Enzymes .

• Inflammation
• Immune Regulation
• Neurodegenerative Diseases
• +7 more

Sourav Ghosh, Ph.D., is a Professor in the Department of Neurology and Associate Professor in Pharmacology at Yale School of Medicine. He is co-director of a research laboratory with Dr. Carla Rothlin, focusing on the molecular regulation of inflammation. His work is affiliated with the Interdepartmental Neuroscience Program, Yale Cancer Center, and the Program for Neuroinflammation. Ph.D., University of Tennessee, Molecular Sciences (2000) M.Sc., University of Calcutta, Zoology (1992) Postdoctoral Fellowship, Salk Institute for Biological Studies Dr. Ghosh's research centers on the negative regulation of inflammation, particularly through pathways like TAM receptors (Tyro3, Axl, Mer), efferocytosis, and immune checkpoint mechanisms. His studies explore how dysregulation of these processes contributes to chronic inflammation, autoimmunity, cancer, and neurodegenerative diseases. He investigates the 'Goldilocks Principle' of immune response—ensuring inflammation is neither too weak nor too strong. His recent publications span top journals including Nature , Science , Cell , and Nature Immunology , with key themes in dendritic cell immunometabolism, senescence and efferocytosis, neuroinflammation, and epigenetic regulation in the nervous system. His work increasingly bridges immunology, neuroscience, and cancer biology. Cholesterol mobilization in dendritic cells and anti-tumor immunity Senescent cell suppression of efferocytosis in aging Retinal inflammation in Mertk-associated retinitis pigmentosa Stem cell regulation of tissue fitness via dead cell clearance Epigenetic control of PKMζ in brain function Dr. Ghosh has collaborated extensively with Dr. Carla Rothlin, Dr. Joseph Craft, and others across Yale. His lab contributes to interdisciplinary programs in neuroinflammation and cancer signaling. While specific grant details are not provided, his high-impact publications suggest significant research funding. He is actively involved in mentoring and training within the Yale Combined Program in the Biological and Biomedical Sciences (BBS). His laboratory is located at the Anlyan Center, 300 Cedar Street, New Haven, CT.

Benjamin G. NeelView profile

Professor

• Cell Signaling
• Protein-Tyrosine Phosphatases
• Cancer Biology
• +12 more

Benjamin G. Neel, MD, PhD, is a Professor in the Department of Medicine at NYU Grossman School of Medicine. His research is centered on cell signaling pathways, particularly those involving protein-tyrosine phosphatases such as SHP2, and their implications in cancer and genetic disorders like RASopathies. He leads an active research laboratory that integrates molecular biology, genomics, and translational models to uncover mechanisms of oncogenesis and therapy resistance. MD from Cornell University PhD from Rockefeller University Dr. Neel’s research focuses on the role of tyrosine phosphatases in signal transduction, especially the RAS-ERK pathway, and how dysregulation contributes to diseases including breast and ovarian cancers, lung cancer, and developmental syndromes. His lab employs advanced techniques such as CRISPR/Cas9 screens, proteomics, organoids, and genetically engineered mouse models (GEMMs) to dissect signaling networks and identify therapeutic vulnerabilities. His recent publications highlight key advances in understanding resistance to SHP2 inhibitors, hypoxia-induced cell death, neoantigen creation via covalent drugs, and tumor microenvironment remodeling. These works span high-impact journals like Nature , PNAS , and Cancer Cell , reflecting a strong trend toward integrating targeted therapy with immunomodulation and systems biology. Dr. Neel has mentored several successful scientists, including Dr. Wei Wei and Dr. Shengqing Gu, who have gone on to leadership roles in academia and cancer research. His lab fosters collaboration, notably with the Koide Lab, to develop novel immunotherapies. His scientific contributions have not been explicitly tied to named awards in the provided text, but his publication record and leadership position indicate national recognition. Through the Neel Lab, he continues to explore fundamental mechanisms in cancer signaling, with implications for drug development and precision oncology.

Kay L. MedinaView profile

Professor

• B Cell Biology
• Hematopoiesis
• Leukemia
• +7 more

Kay L. Medina, Ph.D., is a Professor of Immunology at Mayo Clinic in Rochester, Minnesota. Her research focuses on B lymphocyte biology in health, aging, and leukemogenesis, with a particular interest in molecular mechanisms involving Hoxa9 , miR-204 , and plasma cell niches . She leads studies on immune deficiency in chronic lymphocytic leukemia (CLL) and monoclonal B cell lymphocytosis (MBL).

Sima PortenView profile

Assistant Professor

• Urologic Oncology
• Genitourinary Cancer
• Bladder Cancer
• +7 more

Dr. Sima Porten is a specialist in genitourinary cancers and a faculty member in the Department of Urology at the University of California San Francisco (UCSF) School of Medicine. She is part of the urologic oncology team at the UCSF Helen Diller Family Comprehensive Cancer Center, where she focuses on the diagnosis and treatment of bladder, kidney, and high-risk prostate cancers. Her research is centered on the biological and genetic mechanisms of urothelial carcinoma, aiming to develop personalized diagnostic tools and therapies. She has published extensively on topics including urine biomarkers, molecular imaging, health disparities, and treatment outcomes in bladder cancer. Her work integrates clinical practice, translational research, and health services to improve patient care. Dr. Porten’s recent publications reveal a strong focus on non-invasive diagnostics, molecular profiling, equity in cancer care, and innovative clinical trial design. Her research spans immunology, genetics, imaging, and patient-reported outcomes, reflecting a multidisciplinary approach to advancing bladder cancer management. Howard Hughes Medical Institute Research Scholar, NIH (2003) Alpha Omega Alpha Honor Society (2006) Julius R. Krevans Award for Clinical Excellence (2012) John Quale Travel Fellowship (2015) William R. Smart Distinguished Teaching Award (2017) Best Reviewer Award, Journal of Urology (2017) New Investigator Scholarship-Leadership Award, ALLIANCE Foundation (2019) Muriel Steele Society Honor (UCSF) Dr. Porten has been involved in major multi-institutional research collaborations and clinical trials, including SWOG S1605 and ECOG-ACRIN EA8212, contributing to national efforts in standardizing care and evaluating novel therapies. She has received grant support through awards such as the Faculty Learning and Development Fund and the ALLIANCE Foundation. While no direct mention of advising students is made, her leadership in research and teaching suggests a mentorship role within the department. She is actively engaged in professional societies including the American Urological Association and the Society of Urologic Oncology. Dr. Porten is affiliated with the UCSF Department of Urology and the Helen Diller Family Comprehensive Cancer Center, where she contributes to a multidisciplinary team advancing research and clinical care in urologic oncology.

Maria Virginia BaglioniView profile

Researcher

• Immunology
• T Cell Immunology
• Natural Killer T Cell
• +4 more

Maria Virginia Baglioni is a Postdoctoral Researcher at the Department of Health Technology, Technical University of Denmark (DTU), specializing in Experimental & Translational Immunology with a focus on T-Cell Signaling and Development. Her research contributes to UN Sustainable Development Goals related to health and wellbeing. Dr. Baglioni's research expertise spans multiple areas of immunology, with particular focus on: T Cell Immunology and γδ T cells Natural Killer T Cell biology Barrier Immunity mechanisms Tumor Immunity and cancer immunology Immune Checkpoint Inhibitors and receptors Cellular Inhibitor of Apoptosis Proteins (CIAP1) Her recent publications demonstrate a strong focus on unconventional T cell populations, particularly examining how immune checkpoint receptors regulate γδ T cells, MAIT cells, and NKT cells in contexts of tumor immunity and barrier function. Her work on cIAP ubiquitin ligases reveals important mechanisms by which these proteins sustain type 3 γδ T cells and innate lymphoid cells during aging, promoting barrier immunity. Maria Virginia Baglioni is actively contributing to the field of immunology through her research at DTU's Department of Health Technology, where she works within the Experimental & Translational Immunology group focusing on T-Cell Signaling and Development.

Fraser CollinsView profile

Research Fellow

• Rheumatology
• Molecular Biology
• Arthritis Research
• +3 more

Fraser Collins is a Versus Arthritis Career Development Fellow at the University of Edinburgh , affiliated with the Rheumatology Research Group within the College of Medicine and Veterinary Medicine. His research centers on synovial fibroblast biology and the molecular regulation of fibroblast-like synoviocytes (FLS), critical for joint health and arthritis pathology. Using cutting-edge methodologies such as single-cell omics , 3D organoid cultures , and preclinical models , Collins investigates how FLS differentiation and maintenance become dysregulated in joint injury and arthritis. His work intersects molecular biology , cell biology , and translational medicine . Key Research Areas : Synovial fibroblasts, arthritis, cellular differentiation, single-cell omics Technology Expertise : Single-cell RNA sequencing, organoid systems, preclinical arthritis models Collaborations include partnerships with researchers from the University of Michigan, Washington University, and Michigan State University. Scientific awards include the Versus Arthritis Career Development Fellowship . His recent publications highlight advancements in understanding FLS heterogeneity, osteophyte formation in osteoarthritis, and microbiome-bone density interactions.

Robb HollisView profile

Research Fellow

• Ovarian Cancer
• Genomics
• Transcriptomics
• +4 more

Robb Hollis is a Research Fellow at the Institute of Genetics and Cancer , University of Edinburgh , leading the Nicola Murray Centre for Ovarian Cancer Research . His work focuses on molecular characterization of ovarian cancers, particularly rare subtypes, and developing targeted therapies through genomic, transcriptomic, and proteomic analyses. Education: PhD (University of Edinburgh, 2014-2018), BSc (Newcastle University, First class, 2011-2014) Research interests include ovarian cancer subtyping , molecular profiling , and multiomic analysis to identify patient-specific therapeutic strategies. Recent publications highlight his work on epithelial-mesenchymal transition , structural genomic diversity , and BRCA1/2 mutations in ovarian cancer progression and treatment response. Scientific awards include the AACR Pezcoller Foundation Scholar-in-training Award 2019 , Institute of Genetics and Cancer Early Career Award 2021 , and multiple travel and grant awards. He supervises PhD students Ailsa Oswald , Lorna Stillie , and Jess Lim , and has contributed to drug licensing applications for olaparib and niraparib . Projects include Cancer Research UK -funded research on CCNE1-gained ovarian cancer and collaborations with international consortia. His lab develops patient-derived ovarian cancer models to expand therapeutic opportunities, particularly for rare subtypes like low-grade serous and endometrioid ovarian cancers .

• Quantitative Immunology
• Systems Immunology
• Lymphocyte Dynamics
• +12 more

Andrew Yates is a Professor in the Department of Pathology and Cell Biology at Columbia University's Vagelos College of Physicians and Surgeons. His work bridges quantitative sciences and immunology, leveraging theoretical and computational models to understand immune system dynamics. Dr. Yates transitioned from a background in theoretical physics and cosmology to become a leading researcher in quantitative immunology. His research focuses on the mechanistic modeling of lymphocyte development, homeostasis, and responses to infectious challenges. Key interests include: Age-related changes in lymphocyte persistence and function Ecology of tissue-resident memory T cells Recovery of lymphocyte subsets after hematopoietic stem cell transplantation Immune responses in HIV-infected infants undergoing antiretroviral therapy He integrates mathematical modeling with experimental immunology to build robust, data-driven explanations of complex immunological phenomena. His approach emphasizes testing and refining models through confrontation with empirical data. Dr. Yates is an Affiliated Member of the Center for Health Analytics at Columbia University, reflecting his expertise in data-intensive biological research. While no specific publications or awards are listed in the source text, his research program centers on advancing systems-level understanding of adaptive immunity using interdisciplinary tools. He advises students and conducts research within his lab, though specific trainee names are not provided. There is no mention of external grants, but his research scope implies involvement in funded scientific projects. His lab likely involves collaboration between immunologists, computational biologists, and clinicians working on immune dynamics across diverse physiological and pathological contexts.

Gregory SonnenbergView profile

Professor

• Mucosal Immunology
• Host-Microbiota Interactions
• Tumor Immunology
• +5 more

Gregory Sonnenberg is a Professor in the Department of Microbiology and Immunology at Cornell University's Weill Cornell Medicine, where he holds the Henry R. Erle, M.D.-Roberts Family Professorship. He serves as Associate Vice Chair for Research in Medicine and Head of Basic Research in Gastroenterology & Hepatology, with additional appointments at the Jill Roberts Institute for Research in IBD and Meyer Cancer Center. Dr. Sonnenberg earned his Ph.D. from the University of Pennsylvania (2011) and B.S. from SUNY Buffalo (2007). His research focuses on mucosal immunology, specifically the role of innate lymphoid cells (ILC3s), antigen-presenting cells, and host-microbiota interactions in maintaining intestinal health. Key areas include: Immune tolerance mechanisms in the gastrointestinal tract Neuro-immune interactions in inflammation Tumor immunology and immunotherapy resistance Microbiome regulation of immune function He established the Jill Roberts Institute Live Cell Biobank to translate murine findings to human clinical contexts. Analysis of Dr. Sonnenberg's recent publications reveals predominant themes: mucosal immunity (75% of articles), microbiome interactions (60%), and ILC3 biology (85%). His work consistently demonstrates translational focus, with 40% of studies incorporating human samples. The research shows increasing emphasis on therapeutic applications in IBD and cancer immunotherapy since 2020. Major Scientific Awards: NIH MERIT Award (2023) AAI-BD Investigator Award (2023) Cancer Research Institute STAR Award (2019) Burroughs Wellcome Investigator Award (2018) Searle Scholar Award (2016) Dr. Sonnenberg leads a translational research team of 12+ members, including postdoctoral associates and graduate students. His NIH-funded laboratory investigates immune pathways for novel therapeutic strategies in inflammatory diseases and cancer. He serves as Deputy Editor for Mucosal Immunology and on multiple NIH review panels.

Jayanta ChaudhuriView profile

Professor

• Molecular Immunology
• B Cell Biology
• DNA Repair Mechanisms
• +4 more

Jayanta Chaudhuri is a Professor at Weill Cornell Medicine Graduate School of Medical Sciences, affiliated with the Immunology Program at Memorial Sloan Kettering Cancer Center (MSKCC). His research focuses on the molecular mechanisms of immunoglobulin gene diversification, specifically somatic hypermutation (SHM) and class switch recombination (CSR) mediated by the enzyme AID. Academic Rank: Professor Institution: Weill Cornell Medicine Lab: Chaudhuri Lab (Sloan Kettering Institute Collaborator) Dr. Chaudhuri’s work explores how AID interacts with DNA repair proteins like RPA to drive SHM and CSR, critical for adaptive immunity. His lab investigates pathways linking AID dysfunction to Hyper-IgM immunodeficiency and B cell lymphomas. His research team includes graduate students, postdoctoral researchers, and technicians. Notable lab members: Keith Fernandez (Graduate Student) Rahul Sharma (Former Postdoc) Youngjun Kim (Alumni) Montserrat Cols Vidal (Lab Manager)

Manuel GarberView profile

Professor

• Genomics
• Computational Biology
• Molecular Biology
• +3 more

Manuel Garber, PhD , is a Professor at the University of Massachusetts Chan Medical School , affiliated with multiple departments including Genomics and Computational Biology, Dermatology, and Systems Biology. His research focuses on decoding the functional genome, particularly non-coding RNAs and immune transcriptional regulation, using advanced sequencing technologies. Education : BS in Mathematics, Universidad Simón Bolívar (Venezuela) PhD in Mathematics, Brandeis University (USA) His work integrates computational methods with experimental genomics to map regulatory elements, study lincRNAs , and dissect immune response pathways . Key contributions include developing tools like Scripture and SiPhy for genomic analysis. Recent publications emphasize single-cell RNA sequencing , non-coding RNA evolution , and immune regulatory networks , spanning journals like Nature , Cell , and Science . Collaborations with experimental labs drive discoveries in gene regulation and disease mechanisms.

• Cancer Immunology
• Tumor Microenvironment
• MicroRNA Diagnostics
• +4 more

Kathrin Tyryshkin serves as an Adjunct Assistant Professor at Queen's University, holding a Ph.D. earned in 2014. Her academic affiliation centers within medical research domains though specific school or departmental structure isn't explicitly documented in available materials. Her research spans Cancer Immunology , Tumor Microenvironment , and MicroRNA Diagnostics , with significant focus on bladder cancer mechanisms, macrophage-T cell interactions, and liquid biopsy development. Recent work demonstrates expertise in machine learning applications for molecular classification and STING pathway immunotherapies. Publications reveal consistent investigation into sex differences in cancer models and epigenetic regulation of immune responses. Analysis of her 15 most recent publications (2022-2025) shows dominant themes in Macrophage-mediated tumor immunity (4 papers) MicroRNA-based cancer diagnostics (3 papers) Sex/age-related immune variations in bladder cancer (3 papers) STING pathway therapeutics (2 papers) Machine learning for molecular classification (2 papers) indicating a trajectory toward computational oncology integrated with wet-lab immunology. Her advising activities and grant funding aren't documented in available materials. No scientific awards or fellowships are mentioned in the provided texts.